Subcutaneous administration of testosterone. A pilot study report
- PMID: 17143361
Subcutaneous administration of testosterone. A pilot study report
Abstract
Objective: To investigate the effect of low doses of subcutaneous testosterone in hypogonadal men since the intramuscular route, which is the most widely used form of testosterone replacement therapy, is inconvenient to many patients.
Methods: All men with primary and secondary hypogonadism attending the reproductive endocrine clinic at Royal Victoria Hospital, Monteral, Quebec, Canada, were invited to participate in the study. Subjects were enrolled from January 2002 till December 2002. Patients were asked to self-administer weekly low doses of testosterone enanthate using 0.5 ml insulin syringe.
Results: A total of 22 patients were enrolled in the study. The mean trough was 14.48 +/- 3.14 nmol/L and peak total testosterone was 21.65 +/- 7.32 nmol/L. For the free testosterone the average trough was 59.94 +/- 20.60 pmol/L and the peak was 85.17 +/- 32.88 pmol/L. All of the patients delivered testosterone with ease and no local reactions were reported.
Conclusion: Therapy with weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels. This is the first report, which demonstrated the efficacy of delivering weekly testosterone using this cheap, safe, and less painful subcutaneous route.
Similar articles
-
Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).Clin Endocrinol (Oxf). 2008 Oct;69(4):642-7. doi: 10.1111/j.1365-2265.2008.03251.x. Epub 2008 Apr 3. Clin Endocrinol (Oxf). 2008. PMID: 18394021
-
Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men.BJU Int. 2004 Apr;93(6):789-95. doi: 10.1111/j.1464-410X.2003.04750.x. BJU Int. 2004. PMID: 15049991 Clinical Trial.
-
Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.Int J Impot Res. 2008 Mar-Apr;20(2):213-7. doi: 10.1038/sj.ijir.3901618. Epub 2007 Sep 27. Int J Impot Res. 2008. PMID: 17898800 Clinical Trial.
-
Testosterone treatment comes of age: new options for hypogonadal men.Clin Endocrinol (Oxf). 2006 Sep;65(3):275-81. doi: 10.1111/j.1365-2265.2006.02618.x. Clin Endocrinol (Oxf). 2006. PMID: 16918944 Review.
-
Testosterone Therapy With Subcutaneous Injections: A Safe, Practical, and Reasonable Option.J Clin Endocrinol Metab. 2022 Feb 17;107(3):614-626. doi: 10.1210/clinem/dgab772. J Clin Endocrinol Metab. 2022. PMID: 34698352 Free PMC article.
Cited by
-
Effects of cross-sex hormone treatment on transgender women and men.Obstet Gynecol. 2015 Mar;125(3):605-610. doi: 10.1097/AOG.0000000000000692. Obstet Gynecol. 2015. PMID: 25730222 Free PMC article.
-
The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health.Int J Mol Sci. 2022 Oct 8;23(19):11952. doi: 10.3390/ijms231911952. Int J Mol Sci. 2022. PMID: 36233256 Free PMC article. Review.
-
Pharmacokinetic Profile of Subcutaneous Testosterone Enanthate Delivered via a Novel, Prefilled Single-Use Autoinjector: A Phase II Study.Sex Med. 2015 Sep 17;3(4):269-79. doi: 10.1002/sm2.80. eCollection 2015 Dec. Sex Med. 2015. PMID: 26797061 Free PMC article.
-
Serum Testosterone Concentrations Remain Stable Between Injections in Patients Receiving Subcutaneous Testosterone.J Endocr Soc. 2017 Jul 21;1(8):1095-1103. doi: 10.1210/js.2017-00148. eCollection 2017 Aug 1. J Endocr Soc. 2017. PMID: 29264562 Free PMC article.
-
Pharmacokinetics and Acceptability of Subcutaneous Injection of Testosterone Undecanoate.J Endocr Soc. 2019 Jun 28;3(8):1531-1540. doi: 10.1210/js.2019-00134. eCollection 2019 Aug 1. J Endocr Soc. 2019. PMID: 31384715 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources